Comparing PainReform (NASDAQ:PRFX) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

PainReform (NASDAQ:PRFX) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for PainReform and Eloxx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Eloxx Pharmaceuticals	1	0	2	2	3.00

Eloxx Pharmaceuticals has a consensus price target of $38.33, suggesting a potential upside of 147.15%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than PainReform.

Profitability

This table compares PainReform and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Eloxx Pharmaceuticals	N/A	N/A	N/A

Valuation & Earnings

This table compares PainReform and Eloxx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	40.02	-$5.02 million	($736.66)	-0.00
Eloxx Pharmaceuticals	N/A	N/A	-$5.99 million	($1.54)	-10.07

PainReform has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

PainReform has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1960.42, meaning that its share price is 196,142% less volatile than the S&P 500.

Insider and Institutional Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

PainReform beats Eloxx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.